top of page

ハーバード大学附属病院ベス・イスラエル・ディーコネス・メディカル・センターとOSTRIGEN Inc.の共同研究について

ハーバード大学医学部の主要な教育附属病院ベス・イスラエル・ディーコネス・メディカル・センター(BIDMC)とOSTRIGEN BIOME株式会社の親会社であるオーストリジェンInc.は、ダチョウ由来の抗体を経口投与することでクロストリジウム・デフィシル感染症の治療を行う研究を共同で行うことを発表します。








べス・イスラエル・ディーコネス・メディカル・センター(BIDMC) べス・イスラエル・ディーコネス・メディカル・センターはハーバード大学医学部の教育附属病院、治療目的の病院でありNIHからの予算助成金を受けている独立病院としては常に全米のランクではトップの病院のひとつです。

OSTRIGEN Inc. オーストリジェンInc.は2015年にマサチューセッツ州ウォルサムに設立されました。ダチョウの抗体を使って幅広い用途について病原体やアレルギー物質などに対抗する抗体やそれに関連した製品開発の研究開発を行う会社です。


Beth Israel Deaconess Medical Center (BIDMC), a major teaching hospital of Harvard Medical School, and OstriGen Inc. are announcing a collaborative study of the use of orally administered ostrich antibodies in the treatment of Clostridium difficile infection. C. difficile is resistant to multiple antibiotics, and it is now the single leading cause of hospital-acquired bacterial infection, becoming the deadliest enteric pathogen in the developed world.

The study will focus on the use of antibodies to the toxins produced by C. difficile. Inactivated toxins produced at BIDMC’s C. difficile Laboratory will be injected into ostriches at OstriGen’s facilities in Japan. The ostrich, which is an ancient species of bird, has developed what is believed to be one of the most powerful immune system among land animals. Ostriches produce enormous quantities of antibodies in the yolk of their eggs.

Study participants include Drs. Ciaran Kelly and Xinhua Chen at BIDMC and Dr. Yasuhiro Tsukamoto at Kyoto Prefectural University, Japan. According to Dr. Kelly, “we think that immunotherapy employing oral ingestion of ostrich antibodies could be an effective, economic prophylaxis and treatment for C. difficile infection, fitting into a treatment spectrum between vaccination and antibiotics.” Dr. Tsukamoto has stated that “ostrich antibodies have been developed for oral treatment of several viral and bacterial enteric diseases, and we believe C. diff toxin antibodies will work as well.” Dr. Tsukamoto is also collaborating with the U. S. Army Medical Research Institute of Infectious Diseases in the study of ostrich antibody countermeasures to Ebola, MERS, and Zika.

About Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.

About OstriGen Inc. OstriGen Inc., Waltham, Massachusetts, was formed in 2015 to develop and commercialize ostrich antibodies against a wide range of pathogens and allergens.


bottom of page